Zacks Investment Research cut shares of Metacrine (NASDAQ:MTCR – Get Rating) from a buy rating to a hold rating in a research report report published on Thursday, Zacks.com reports. According to Zacks, “Metacrine Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing therapies for patients with liver and gastrointestinal diseases. The […]